In a signal that it may seek monetary relief from pharmaceutical companies involved in so-called “pay-for-delay” agreements and from other firms engaged in other conduct believed to be anticompetitive, the Federal Trade Commission announced that it has withdrawn an earlier policy statement on monetary relief in antitrust cases in favor of a more flexible, and potentially more aggressive, approach. Coming one week after achieving a major victory in the Third Circuit which breathed new life into the agency’s campaign against pay-for-delay settlements, the agency’s action seems especially directed at that conduct, though companies outside the pharmaceutical area should also take note.
In 2003, the FTC issued its Policy Statement on Monetary Equitable Remedies in Competition Cases. That statement outlined a framework for determining when the Commission would seek equitable monetary remedies, such as disgorgement of ill-gotten gains, in competition cases.
Specifically, the 2003 Policy Statement focused on three factors as relevant to whether the Commission would seek monetary relief: (1) whether the challenged conduct is “clear”; (2) whether there is a reasonable basis to calculate the remedial payment; and (3) whether remedies in other civil or criminal litigation are likely to accomplish fully the purposes of the antitrust laws.
Please see full alert below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.